An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Chronic hepatitis C genotype 1 * Treatment-naïve, i.e. have not been previously treated with pegylated interferon, standard interferon and ribavirin * Confirmed serum positive HCV RNA * Liver fibrosis confirmed histologically or by fibroscan up to 24 months before treatment Exclusion Criteria: * Any contraindications according to the Summary of Product Characteristics for Pegasys or Copegus * Co-infection with hepatitis B or HIV * Post-transplant patients * End stage renal disease (creatinine clearance \< 15 ml/min) * Patients treated with immunotherapy * Pregnant women and male partners of women who are pregnant * Female patients of childbearing potential and male patients with female partners of childbearing potential who are unable or unwilling to use effective and continuous contraception during the treatment and for 4 months (females) and 7 months (males) thereafter